Feagan, Brian G.

Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn’s disease: unexpected results of a randomised, double-blind placebo-controlled trial

Hueber, W., Sands, B. E., Lewitzky, S., Vandemeulebroecke, M., Reinisch, W., Higgins, P. D. R., Wehkamp, J., Feagan, B. G., Yao, M. D., Karczewski, M., et al. (2012) · Gut

Inflammatory Bowel DiseasePsoriasis: Treatment and Pathogenesis

Cited by 1,547

Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study

Feagan, B. G., Sandborn, W. J., D'Haens, G., Panés, J., Kaser, A., Ferrante, M., Louis, E., Franchimont, D., Dewit, O., Seidler, U., et al. (2017) · The Lancet

Inflammatory Bowel DiseasePsoriasis: Treatment and Pathogenesis

Cited by 451

A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Brodalumab in Patients With Moderate-to-Severe Crohn’s Disease

Targan, S. R., Feagan, B., Vermeire, S., Panaccione, R., Melmed, G. Y., Landers, C., Li, D., Russell, C., Newmark, R., Zhang, N., et al. (2016) · American Journal of Gastroenterology

Inflammatory Bowel DiseasePsoriasis: Treatment and Pathogenesis

Cited by 383

Efficacy and Safety of Upadacitinib in a Randomized Trial of Patients With Crohn’s Disease

Sandborn, W. J., Feagan, B. G., Loftus, E. V., Peyrin-Biroulet, L., Van Assche, G., D’Haens, G., Schreiber, S., Colombel, J.-F., Lewis, J. D., Ghosh, S., et al. (2020) · Gastroenterology

Inflammatory Bowel DiseaseRheumatoid Arthritis Research and Therapies

Cited by 322

Efficacy and Safety of MEDI2070, an Antibody Against Interleukin 23, in Patients With Moderate to Severe Crohn’s Disease: A Phase 2a Study

Sands, B. E., Chen, J., Feagan, B. G., Penney, M., Rees, W. A., Danese, S., Higgins, P. D. R., Newbold, P., Faggioni, R., Patra, K., et al. (2017) · Gastroenterology

Inflammatory Bowel DiseasePsoriasis: Treatment and Pathogenesis

Cited by 279

A Simplified Approach to the Treatment of Uncomplicated Hypertension: A Cluster Randomized, Controlled Trial

Feldman, R. D., Zou, G. Y., Vandervoort, M. K., Wong, C. J., Nelson, S. A. E., & Feagan, B. G. (2009) · Hypertension

Blood Pressure and Hypertension StudiesClinical practice guidelines implementation

Cited by 239

Converging goals of treatment of inflammatory bowel disease from clinical trials and practice

Levesque, B. G., Sandborn, W. J., Ruel, J., Feagan, B. G., Sands, B. E., & Colombel, J.-F. (2015) · Gastroenterology

Inflammatory Bowel DiseaseOcular Diseases and Behçet’s Syndrome

Cited by 217

Novel Fecal Biomarkers That Precede Clinical Diagnosis of Ulcerative Colitis

Galipeau, H. J., Caminero, A., Turpin, W., Bermudez-Brito, M., Santiago, A., Libertucci, J., Constante, M., Raygoza Garay, J. A., Rueda, G., Armstrong, S., et al. (2021) · Gastroenterology

Gut microbiota and healthInflammatory Bowel Disease

Cited by 190

An international consensus to standardize integration of histopathology in ulcerative colitis clinical trials

Ma, C., Sedano, R., Almradi, A., Vande Casteele, N., Parker, C. E., Guizzetti, L., Schaeffer, D. F., Riddell, R. H., Pai, R. K., Battat, R., et al. (2021) · Gastroenterology

Inflammatory Bowel DiseaseMicroscopic Colitis

Cited by 105

An expert consensus to standardise the assessment of histological disease activity in Crohn's disease clinical trials

Almradi, A., Ma, C., D'Haens, G. R., Sandborn, W. J., Parker, C. E., Guizzetti, L., Borralho Nunes, P., De Hertogh, G., Feakins, R. M., Khanna, R., et al. (2021) · Alimentary Pharmacology & Therapeutics

Inflammatory Bowel DiseaseOcular Diseases and Behçet’s Syndrome

Cited by 34

Inflammatory bowel disease: healthcare costs for patients who are adherent or non-adherent with infliximab therapy

Wan, G. J., Kozma, C. M., Slaton, T. L., Olson, W. H., & Feagan, B. G. (2014) · Journal of Medical Economics

Inflammatory Bowel DiseaseMedication Adherence and Compliance

Cited by 33